Breakfast Technical Briefing on Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, La Jolla Pharma, and Moleculin Biotech
NEW YORK, August 2, 2017 /PRNewswire/ --
If you want a Stock Review on DVAX, KERX, LJPC, or MBRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Today, DailyStockTracker.com reviews Dynavax Technologies Corp. (NASDAQ: DVAX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), and Moleculin Biotech Inc. (NASDAQ: MBRX). Based on trends historically seen in August, Jeff Hirsch, market-timing specialist and editor of Stock Trader's Almanac, said that the Biotech sector enters its historical favorable season this month. iShares NASDAQ Biotech could be bought on dips below $277.00. The stop loss is $249.30, and auto sell is $349.49. Daily Stock Tracker published free research reports on these stocks today at:
http://dailystocktracker.com/register/
Dynavax Technologies
Berkeley, California headquartered Dynavax Technologies Corp.'s shares dropped 4.10%, closing Tuesday's trading session at $15.20. The stock recorded a trading volume of 6.94 million shares, which was above its three months average volume of 2.17 million shares. The Company's shares have surged 52.00% in the last month, 173.87% over the previous three months, and 284.81% since the start of this year. The stock is trading 80.33% above its 50-day moving average and 137.42% above its 200-day moving average. Additionally, shares of Dynavax Technologies have a Relative Strength Index (RSI) of 74.14.
On July 28th, 2017, Dynavax Technologies announced that the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 12 to 1 that the safety data for HEPLISAV-B (Hepatitis B Vaccine, Recombinant [Adjuvanted]) support licensure for immunization against hepatitis B infection in adults 18 years of age and older. Three members of the panel abstained. A prior VRBPAC panel voted 13 to 1 that the data from Phase-3 clinical trials supports the immunogenicity of HEPLISAV-B.
On July 31st, 2017, research firm RBC Capital Markets upgraded the Company's stock rating from 'Sector Perform' to 'Outperform' while revising its previous target price from $7 a share to $26 a share. See our free and comprehensive research report on DVAX at:
http://dailystocktracker.com/registration/?symbol=DVAX
Keryx Biopharma
On Tuesday, shares in Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc. recorded a trading volume of 1.11 million shares. The stock rose 0.29%, ending the day at $7.03. The Company's shares have advanced 20.79% in the previous three months and 19.97% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.58% and 18.56%, respectively. Furthermore, shares of Keryx Biopharma have an RSI of 44.10.
On July 27th, 2017, Keryx Biopharma announced its financial results for the quarter ended June 30th, 2017. Total revenues for Q2 2017 were $15.1 million, cost of goods sold was $4.4 million, and net loss was $86.5 million. Cash and cash equivalents as of June 30th, 2017 totaled $140.5 million compared to $111.8 million as of December 31st, 2016. KERX free research report is just a click away at:
http://dailystocktracker.com/registration/?symbol=KERX
La Jolla Pharma
San Diego, California headquartered La Jolla Pharmaceutical Co.'s stock finished the day 4.02% higher at $30.82 with a total trading volume of 204,589 shares. The Company's shares have advanced 3.53% in the last one month, 9.72% in the previous three months, and 75.81% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.07% and 21.87%, respectively. Additionally, shares of La Jolla Pharma have an RSI of 45.22.
On July 27th, 2017, La Jolla Pharma reported financial results for the three and six months ended June 30th, 2017. The Company had $141.3 million in cash and cash equivalents as of June 30th, 2017. Cash used in operating activities for the six months ended June 30th, 2017 was $41.9 million. Net loss for the three and six months ended June 30th, 2017 was $26.7 million and $50.0 million, or $1.21 per share and $2.46 per share, respectively. Sign up for your complimentary report on LJPC at:
http://dailystocktracker.com/registration/?symbol=LJPC
Moleculin Biotech
Shares in Houston, Texas headquartered Moleculin Biotech Inc. ended yesterday's session 9.36% lower at $2.71. The stock recorded a trading volume of 9.48 million shares, which was above its three months average volume of 2.82 million shares. The Company's shares have advanced 44.92% in the last one month, 211.14% over the previous three months, and 18.86% since the start of this year. The stock is trading 93.01% and 58.22% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Moleculin Biotech have an RSI of 66.83.
On July 27th, 2017, Moleculin Biotech announced the appointment of John M. Climaco as an independent member of the Company's Board of Directors, effective July 24th, 2017, to fill a board vacancy. Climaco, 48, was most recently the Executive Vice President of Perma-Fix Medical S.A, a Polish subsidiary of the Perma-Fix Environmental Services, Inc., where he has served as a director since 2013. Register for free on DailyStockTracker.com and download the latest research report on MBRX at:
http://dailystocktracker.com/registration/?symbol=MBRX
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article